ArticleCancer immunology, immunotherapy : CII2026
Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeck dissection and adequate lymph node yield (LNY) are important in the treatment of head and neck squamous cell carcinoma (HNSCC). Cervical lymph nodes represent the primary sites for T-cell priming; however, the impact of LNY on the efficacy of immune checkpoint inhibitors (ICIs) remains unclear.
methodsA total of 120 patients with HNSCC who relapsed after surgical resection and subsequently received ICIs were included. The association of LNY, neutrophil-lymphocyte ratio (NLR), and programmed death-ligand 1 (PD-L1) expression with ICI outcomes were evaluated.
resultsAmong 120 patients, 31 underwent unilateral, 82 bilateral, and 7 no neck dissection. The median LNY was 26 (mean, 29.9; range, 0-145). PD-L1 expression was evaluated in 80 patients, 69 of whom had combined positive score ≥ 1. The low-LNY group had a higher overall response rate to ICI than the high-LNY group (42.9% vs. 16.9%, P = 0.003). Patients with high LNY had inferior PFS (median, 1.3 vs. 5.9 months; P < 0.001) and OS (median, 9.7 vs. 21.1 months; P = 0.007) compared with those with low LNY. In multivariable analysis, high LNY and high NLR were independent predictors of poor survival, whereas PD-L1 expression was not. Among patients with PD-L1-positive tumors, those with high NLR had inferior survivals compared with those with low NLR.
conclusionsExtensive lymphatic ablation, as reflected by high LNY, may be associated with diminished ICI efficacy in relapsed HNSCC. These findings suggest that LNY warrants further investigation as a potential biomarker for ICI outcomes in patients with post-surgical recurrent HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.